tislelizumab
beigene,novartis
beigene announces late-breaking data at esmo gi showing overall survival benefit for tislelizumab plus chemotherapy in first-line advanced or metastatic esophageal squamous cell carcinoma 
The Headlines of Today is a World News Website, Provide World News, International Breaking News, Tech , spots and entertainment News